Novacyt S.A. (EPA:ALNOV)
France · Delayed Price · Currency is EUR 0.5310
+0.0410 (8.37%)
Aug 21, 2026, 5:35 PM CET
Novacyt Financials Overview
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 20.03 | 20.03 | 19.63 | 10.62 | 21.04 | 92.6 |
Revenue Growth | 2.98% | 2.03% | 84.82% | -49.52% | -77.28% | -66.59% |
Gross Profit Gross Profit Growth | 11.52 | 11.52 | 31.14 | 3.05 | 5.75 | 63.5 |
Operating Income Operating Income Growth | -12.43 | -12.43 | -16.66 | -15.83 | -23.39 | 37.03 |
Net Income Net Income Growth | -22.88 | -22.88 | -41.76 | -28.29 | -25.73 | -9.73 |
Earnings Per Share EPS Growth | -0.32 | -0.32 | -0.59 | -0.40 | -0.36 | -0.14 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Yourgene Health Yourgene Health Growth | 15.97 | 15.97 | 15.28 | 5.63 | - | - |
Primer Design Primer Design Growth | 4.06 | 4.06 | 4.35 | 4.99 | 19.63 | 89.86 |
Total Total Growth | 20.03 | 20.03 | 19.63 | 10.62 | 21.04 | 92.6 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19.27 | 19.27 | 30.64 | 44.17 | 86.98 | 101.77 |
Total Debt Total Debt Growth | 10.45 | 10.45 | 11.88 | 13.7 | 0.87 | 1.87 |
Net Cash (Debt) Net Cash Growth | 8.82 | 8.82 | 18.76 | 30.47 | 86.11 | 99.9 |
Net Cash Growth | -30.97% | -53.00% | -38.43% | -64.62% | -13.80% | 11.75% |
Net Cash Per Share Net Cash Per Share Growth | 0.12 | 0.12 | 0.27 | 0.43 | 1.22 | 1.41 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -9.21 | -9.21 | -9.82 | -25.45 | -13.73 | 15.69 |
Capital Expenditures CapEx Growth | -0.27 | -0.27 | -1.28 | -0.52 | -0.16 | -3.77 |
Free Cash Flow Free Cash Flow Growth | -9.48 | -9.48 | -11.1 | -25.96 | -13.89 | 11.92 |
Free Cash Flow Growth | - | - | - | - | - | -88.31% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 57.49% | 57.49% | 158.65% | 28.70% | 27.31% | 68.57% |
Operating Margin | -62.08% | -62.08% | -84.87% | -149.02% | -111.18% | 39.99% |
Pretax Margin | -136.53% | -136.53% | -200.87% | -230.34% | -95.31% | -6.11% |
Profit Margin | -114.25% | -114.25% | -212.73% | -266.38% | -122.29% | -10.51% |
FCF Margin | -47.34% | -47.34% | -56.57% | -244.45% | -65.99% | 12.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 7.80 | 7.80 | 7.80 | 7.80 | 7.80 |
P/FCF Ratio | - | - | - | - | - | 21.80 |
PS Ratio | 1.68 | 1.20 | 1.79 | 4.11 | 3.66 | 2.81 |